Augmentation Better Than Switching Drugs in MDD

by U.S. Medicine

October 16, 2017

Somaia Mohamed, MD, PhD, of the VA Connecticut Healthcare System in West Haven, led the VA Augmentation and Switching Treatments for Improving Depression Outcomes (VAST-D) Study.

WEST HAVEN, CT — The addition of an atypical anti-psychotic medication to an antidepressant regimen for veterans not responding to their current treatment led to greater improvement in symptoms of depression than switching to another antidepressant altogether.

That’s according to a VA-led clinical trial published recently in the Journal of the American Medical Association.1

“This is the largest study ever performed of ‘next-step’ pharmacotherapy for patients who did not have an adequate response to initial antidepressant pharmacotherapy,” said Paul B. Hicks, MD, PhD, vice dean and professor of psychiatry and behavioral sciences at the Texas A&M College of Medicine in Temple and one of 12 clinicans on the study’s executive committee. “This is the best and largest comparison of switching vs. augmentation strategies for ‘next-step’ pharmacotherapy that has been published. This study looks at the safety and efficacy of the use of a second-generation antipsychotic as an augmentation strategy for treatment-resistant depression.”

Results of the study, led by researchers from the VA New England Mental Illness Research, Education, and Clinical Center, at the VA Connecticut Healthcare System in West Haven indicated a significantly greater likelihood of near-complete relief of depressive symptoms during the 12-week acute-treatment phase.

The 12-week follow-up of a randomized clinical trial of 1,522 patients with major depressive disorder (85% men) unresponsive to previous antidepressant treatment found that 29% achieved remission after augmenting their antidepressant with the antipsychotic aripiprazole vs. 22% who switched to the antidepressant bupropion. Other remission comparisons were not significant.

Study authors suggested that augmentation with aripiprazole resulted in a statistically significant, but only modestly increased likelihood of remission during 12 weeks of treatment, compared with switching to bupropion alone.

The study was conducted from December 2012 to May 2015 at VHA medical centers among patients who were diagnosed with nonpsychotic major depressive disorder (MDD). Participants had been unresponsive to at least one antidepressant course meeting minimal standards for treatment dose and duration.

“Among a predominantly male population with major depressive disorder unresponsive to antidepressant treatment, augmentation with aripiprazole resulted in a statistically significant but only modestly increased, likelihood of remission during 12 weeks of treatment compared with switching to bupropion monotherapy,” researchers concluded. “Given the small effect size and adverse effects associated with aripiprazole, further analysis including cost-effectiveness is needed to understand the net utility of this approach.”

  1. Mohamed S, Johnson GR, Chen P, Hicks PB, Davis LL, et. al. Effect of Antidepressant Switching vs. Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial. JAMA. 2017 Jul 11;318(2):132-145. doi: 10.1001/jama.2017.8036. PubMed PMID: 28697253

 


Related Articles

Bill to Streamline, Expand VA’s Choice Program Signed Into Law

Legislation that would streamline VA’s community care programs into one program and expand VA’s caregiver program to veterans of all eras was signed into law earlier this month..

Despite Criticism, VA Healthcare as Good or Better Than Other Systems

The good news from a recent consultant study is that, overall, the VA healthcare system is generally equal or better than others when inpatient and outpatient quality is measured.


U.S. Medicine Recommends


More From department of veterans affairs

Department of Veterans Affairs (VA)

Bill to Streamline, Expand VA’s Choice Program Signed Into Law

Legislation that would streamline VA’s community care programs into one program and expand VA’s caregiver program to veterans of all eras was signed into law earlier this month..

Department of Veterans Affairs (VA)

Despite Criticism, VA Healthcare as Good or Better Than Other Systems

The good news from a recent consultant study is that, overall, the VA healthcare system is generally equal or better than others when inpatient and outpatient quality is measured.

Department of Veterans Affairs (VA)

VA Inks Contract for Massive New Health Record System

Calling it one of the largest IT contracts in the federal government, with a ceiling of $10 billion over a decade, then-VA Acting Secretary Robert Wilkie announced that the agency signed a contract with Cerner for its new electronic health record (EHR).

Department of Veterans Affairs (VA)

Surprise! President Nominates Wilkie for Permanent VA Secretary

President Donald Trump said last month that acting VA Secretary Robert Wilkie “has done an incredible job” and, in a surprise move, nominated him for the permanent Cabinet position.

Department of Veterans Affairs (VA)

Fibromyalgia Presents Differently in Male, Female Veterans

Research on fibromyalgia, a poorly understood, chronically disabling pain syndrome, generally has focused on its clinical presentation and treatment.

Facebook Comment

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up